Characterization of the Vasorelaxant Mechanisms of the Endocannabinoid Anandamide in Rat Aorta

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2007 Aug 21

PMID 17704831

Citations 27

Authors

E Herradon

M I Martin

V Lopez-Miranda

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Studies in isolated preparations of vascular tissue (mainly resistance vessels) provide evidence that anandamide exerts vasorelaxation. The aim of the present work was to further characterize the mechanisms involved in the vascular response induced by anandamide in a conduit vessel, rat aorta.

Experimental Approach: Isometric tension changes in response to a cumulative concentration-response curve of anandamide (1 nM-100 micro M) were recorded in aortic rings from male Wistar rats. The involvement of a number of factors in this relaxation was investigated including endothelium-derived vasorelaxant products, cannabinoid and vanilloid receptors (transient potential vanilloid receptor-1 (TRPV1)), release of calcitonin gene-related peptide (CGRP), anandamide metabolism and the membrane transporter for anandamide.

Key Results: Anandamide caused a significant concentration-dependent vasorelaxation in rat aorta. This vasorelaxation was significantly inhibited by Pertussis toxin, by a non-CB1/non-CB2 cannabinoid receptor antagonist, by endothelial denudation, by inhibition of nitric oxide synthesis or inhibition of prostanoid synthesis via cyclooxygenase-2 (COX-2), by blockade of prostaglandin receptors EP4 and by a fatty acid amino hydrolase inhibitor. Antagonists for CB1, CB2, TRPV1 or CGRP receptors, an inhibitor of the release of endothelium-derived hyperpolarizing factor, and an inhibitor of anandamide transport did not modify the vascular response to anandamide.

Conclusions And Implications: Our results demonstrate, for the first time, the involvement of the non-CB1/non-CB2 cannabinoid receptor and an anandamide-arachidonic acid-COX-2 derived metabolite (which acts on EP4 receptors) in the endothelial vasorelaxation caused by anandamide in rat aorta.

Citing Articles

Pharmacognosy and Effects of Cannabinoids in the Vascular System.

Mensah E, Tabrizchi R, Daneshtalab N ACS Pharmacol Transl Sci. 2022; 5(11):1034-1049.

PMID: 36407955 PMC: 9667477. DOI: 10.1021/acsptsci.2c00141.

Exploration of Lamiaceae in Cardio Vascular Diseases and Functional Foods: Medicine as Food and Food as Medicine.

Chakrabartty I, Mohanta Y, Nongbet A, Mohanta T, Mahanta S, Das N Front Pharmacol. 2022; 13:894814.

PMID: 35774598 PMC: 9237463. DOI: 10.3389/fphar.2022.894814.

Characterization of hypotensive and vasorelaxant effects of PHAR-DBH-Me a new cannabinoid receptor agonist.

Lopez-Canales O, Pavon N, Ubaldo-Reyes L, Juarez-Oropeza M, Torres-Duran P, Regla I Korean J Physiol Pharmacol. 2022; 26(2):77-86.

PMID: 35203058 PMC: 8890940. DOI: 10.4196/kjpp.2022.26.2.77.

Proangiogenic Effect of Affinin and an Ethanolic Extract from Roots: Ex Vivo and In Vivo Evidence.

Garcia-Badillo P, Avalos-Soriano A, Lopez-Martinez J, Garcia-Gasca T, Castro-Ruiz J Molecules. 2021; 26(24).

PMID: 34946751 PMC: 8706137. DOI: 10.3390/molecules26247670.

Cannabinoids-A New Perspective in Adjuvant Therapy for Pulmonary Hypertension.

Krzyzewska A, Baranowska-Kuczko M, Minczuk K, Kozlowska H Int J Mol Sci. 2021; 22(18).

PMID: 34576212 PMC: 8472313. DOI: 10.3390/ijms221810048.

References

Jarai Z, Wagner J, Varga K, Lake K, Compton D, Martin B . Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A. 1999; 96(24):14136-41. PMC: 24203. DOI: 10.1073/pnas.96.24.14136. View

Randall M, Harris D, Kendall D, Ralevic V . Cardiovascular effects of cannabinoids. Pharmacol Ther. 2002; 95(2):191-202. DOI: 10.1016/s0163-7258(02)00258-9. View

Burstein S, Rossetti R, Yagen B, Zurier R . Oxidative metabolism of anandamide. Prostaglandins Other Lipid Mediat. 2000; 61(1-2):29-41. DOI: 10.1016/s0090-6980(00)00053-8. View

Zygmunt P, Chuang H, Movahed P, Julius D, Hogestatt E . The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur J Pharmacol. 2000; 396(1):39-42. DOI: 10.1016/s0014-2999(00)00207-7. View

Hillard C . Endocannabinoids and vascular function. J Pharmacol Exp Ther. 2000; 294(1):27-32. View

Ralevic V, Kendall D, Randall M, Zygmunt P, Movahed P, Hogestatt E . Vanilloid receptors on capsaicin-sensitive sensory nerves mediate relaxation to methanandamide in the rat isolated mesenteric arterial bed and small mesenteric arteries. Br J Pharmacol. 2000; 130(7):1483-8. PMC: 1572215. DOI: 10.1038/sj.bjp.0703456. View

Hillard C, Jarrahian A . The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes. Chem Phys Lipids. 2000; 108(1-2):123-34. DOI: 10.1016/s0009-3084(00)00191-2. View

Kunos G, Jarai Z, Batkai S, Goparaju S, Ishac E, Liu J . Endocannabinoids as cardiovascular modulators. Chem Phys Lipids. 2000; 108(1-2):159-68. DOI: 10.1016/s0009-3084(00)00194-8. View

Engler M, Engler M, Browne A, Sun Y, Sievers R . Mechanisms of vasorelaxation induced by eicosapentaenoic acid (20:5n-3) in WKY rat aorta. Br J Pharmacol. 2001; 131(8):1793-9. PMC: 1572512. DOI: 10.1038/sj.bjp.0703754. View

10.

Petitcolin M, Vandeputte C, Bueb J, Capdeville-Atkinson C, Tschirhart E . Lack of involvement of pertussis toxin-sensitive G-proteins in norepinephrine-induced vasoconstriction of rat aorta smooth muscle. Biochem Pharmacol. 2001; 61(4):485-91. DOI: 10.1016/s0006-2952(00)00547-5. View

11.

Ralevic V, Kendall D . Cannabinoid inhibition of capsaicin-sensitive sensory neurotransmission in the rat mesenteric arterial bed. Eur J Pharmacol. 2001; 418(1-2):117-25. DOI: 10.1016/s0014-2999(01)00940-2. View

12.

White R, Ho W, Bottrill F, Ford W, Hiley C . Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries. Br J Pharmacol. 2001; 134(4):921-9. PMC: 1573021. DOI: 10.1038/sj.bjp.0704333. View

13.

Grainger J . Anandamide-induced relaxation of sheep coronary arteries: the role of the vascular endothelium, arachidonic acid metabolites and potassium channels. Br J Pharmacol. 2001; 134(5):1003-12. PMC: 1573033. DOI: 10.1038/sj.bjp.0704340. View

14.

Ford W, Honan S, White R, Hiley C . Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br J Pharmacol. 2002; 135(5):1191-8. PMC: 1573229. DOI: 10.1038/sj.bjp.0704565. View

15.

Mukhopadhyay S, Chapnick B, Howlett A . Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent. Am J Physiol Heart Circ Physiol. 2002; 282(6):H2046-54. DOI: 10.1152/ajpheart.00497.2001. View

16.

Ross R, Craib S, Stevenson L, Pertwee R, Henderson A, Toole J . Pharmacological characterization of the anandamide cyclooxygenase metabolite: prostaglandin E2 ethanolamide. J Pharmacol Exp Ther. 2002; 301(3):900-7. DOI: 10.1124/jpet.301.3.900. View

17.

Sugiura T, Kobayashi Y, Oka S, WAKU K . Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins Leukot Essent Fatty Acids. 2002; 66(2-3):173-92. DOI: 10.1054/plef.2001.0356. View

18.

Fowler C, Jacobsson S . Cellular transport of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide--targets for drug development?. Prostaglandins Leukot Essent Fatty Acids. 2002; 66(2-3):193-200. DOI: 10.1054/plef.2001.0357. View

19.

Kozak K, Marnett L . Oxidative metabolism of endocannabinoids. Prostaglandins Leukot Essent Fatty Acids. 2002; 66(2-3):211-20. DOI: 10.1054/plef.2001.0359. View

20.

Glaser S, Abumrad N, Fatade F, Kaczocha M, Studholme K, Deutsch D . Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci U S A. 2003; 100(7):4269-74. PMC: 153082. DOI: 10.1073/pnas.0730816100. View